Cargando…

The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis

The purpose of this meta-analysis was aimed to evaluate the association of tumor protein p53 (TP53) gene codon 72 polymorphism with leukemia susceptibility. We searched PubMed to identify relevant studies, and 16 case-control studies from 14 published articles were identified as eligible studies, in...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Xiao-Lan, Li, Sheng, Meng, Xiang-Yu, Geng, Peiliang, Gao, Qing-Ping, Ao, Xu-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635761/
https://www.ncbi.nlm.nih.gov/pubmed/26402821
http://dx.doi.org/10.1097/MD.0000000000001588
_version_ 1782399550085922816
author Ruan, Xiao-Lan
Li, Sheng
Meng, Xiang-Yu
Geng, Peiliang
Gao, Qing-Ping
Ao, Xu-Bin
author_facet Ruan, Xiao-Lan
Li, Sheng
Meng, Xiang-Yu
Geng, Peiliang
Gao, Qing-Ping
Ao, Xu-Bin
author_sort Ruan, Xiao-Lan
collection PubMed
description The purpose of this meta-analysis was aimed to evaluate the association of tumor protein p53 (TP53) gene codon 72 polymorphism with leukemia susceptibility. We searched PubMed to identify relevant studies, and 16 case-control studies from 14 published articles were identified as eligible studies, including 2062 leukemia patients and 5826 controls. After extracting data, odds ratio (OR) with the corresponding 95% confidence interval (95%CI) was applied to assess the association between TP53 codon 72 polymorphism and leukemia susceptibility. The meta-analysis was performed with the Comprehensive Meta-Analysis software, version 2.2. Overall, no significant association between TP53 codon 72 polymorphism and leukemia susceptibility was found in this meta-analysis (Pro vs Arg: OR = 1.05, 95%CI = 0.90–1.21; Pro/Pro vs Arg/Arg: OR = 1.13, 95%CI = 0.84–1.52; Arg/Pro vs Arg/Arg: OR = 0.94, 95%CI = 0.76–1.15; [Pro/Pro + Arg/Pro] vs Arg/Arg: OR = 0.99, 95%CI = 0.80–1.21; Pro/Pro vs [Arg/Arg + Arg/Pro]: OR = 1.19, 95%CI = 0.93–1.51). Similar results were also found in subgroup analysis by ethnicity, source of controls, and types of leukemia (either acute myeloid leukemia or acute lymphocytic leukemia). Our meta-analysis demonstrates that TP53 codon 72 polymorphism may not be a risk factor for acute leukemia; however, due to the limitations of this study, it should be verified in future studies.
format Online
Article
Text
id pubmed-4635761
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-46357612015-12-16 The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis Ruan, Xiao-Lan Li, Sheng Meng, Xiang-Yu Geng, Peiliang Gao, Qing-Ping Ao, Xu-Bin Medicine (Baltimore) 4800 The purpose of this meta-analysis was aimed to evaluate the association of tumor protein p53 (TP53) gene codon 72 polymorphism with leukemia susceptibility. We searched PubMed to identify relevant studies, and 16 case-control studies from 14 published articles were identified as eligible studies, including 2062 leukemia patients and 5826 controls. After extracting data, odds ratio (OR) with the corresponding 95% confidence interval (95%CI) was applied to assess the association between TP53 codon 72 polymorphism and leukemia susceptibility. The meta-analysis was performed with the Comprehensive Meta-Analysis software, version 2.2. Overall, no significant association between TP53 codon 72 polymorphism and leukemia susceptibility was found in this meta-analysis (Pro vs Arg: OR = 1.05, 95%CI = 0.90–1.21; Pro/Pro vs Arg/Arg: OR = 1.13, 95%CI = 0.84–1.52; Arg/Pro vs Arg/Arg: OR = 0.94, 95%CI = 0.76–1.15; [Pro/Pro + Arg/Pro] vs Arg/Arg: OR = 0.99, 95%CI = 0.80–1.21; Pro/Pro vs [Arg/Arg + Arg/Pro]: OR = 1.19, 95%CI = 0.93–1.51). Similar results were also found in subgroup analysis by ethnicity, source of controls, and types of leukemia (either acute myeloid leukemia or acute lymphocytic leukemia). Our meta-analysis demonstrates that TP53 codon 72 polymorphism may not be a risk factor for acute leukemia; however, due to the limitations of this study, it should be verified in future studies. Wolters Kluwer Health 2015-09-25 /pmc/articles/PMC4635761/ /pubmed/26402821 http://dx.doi.org/10.1097/MD.0000000000001588 Text en Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-nc-sa/4.0
spellingShingle 4800
Ruan, Xiao-Lan
Li, Sheng
Meng, Xiang-Yu
Geng, Peiliang
Gao, Qing-Ping
Ao, Xu-Bin
The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title_full The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title_fullStr The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title_full_unstemmed The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title_short The Role of TP53 Gene Codon 72 Polymorphism in Leukemia: A PRISMA-Compliant Systematic Review and Meta-Analysis
title_sort role of tp53 gene codon 72 polymorphism in leukemia: a prisma-compliant systematic review and meta-analysis
topic 4800
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4635761/
https://www.ncbi.nlm.nih.gov/pubmed/26402821
http://dx.doi.org/10.1097/MD.0000000000001588
work_keys_str_mv AT ruanxiaolan theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT lisheng theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT mengxiangyu theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT gengpeiliang theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT gaoqingping theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT aoxubin theroleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT ruanxiaolan roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT lisheng roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT mengxiangyu roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT gengpeiliang roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT gaoqingping roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis
AT aoxubin roleoftp53genecodon72polymorphisminleukemiaaprismacompliantsystematicreviewandmetaanalysis